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Parallel Synthesis of Cell-Penetrating Peptide Conjugates
of PMO Toward Exon Skipping Enhancement
in Duchenne Muscular Dystrophy
Liz O’Donovan, Itaru Okamoto,* Andrey A. Arzumanov, Donna L. Williams,
Peter Deuss,{ and Michael J. Gait
We describe two new methods of parallel chemical synthesis of libraries of peptide conjugates of phosphoro-
diamidate morpholino oligonucleotide (PMO) cargoes on a scale suitable for cell screening prior to in vivo analysis
for therapeutic development. The methods represent an extension of the SELection of PEPtide CONjugates
(SELPEPCON) approach previously developed for parallel peptide-peptide nucleic acid (PNA) synthesis. How-
ever, these new methods allow for the utilization of commercial PMO as cargo with both C- and N-termini
unfunctionalized. The synthetic methods involve conjugation in solution phase, followed by rapid purification via
biotin-streptavidin immobilization and subsequent reductive release into solution, avoiding the need for painstaking
high-performance liquid chromatography purifications. The synthesis methods were applied for screening of PMO
conjugates of a 16-member library of variants of a 10-residue ApoE peptide, which was suggested for blood-brain
barrier crossing. In this work the conjugate library was tested in an exon skipping assay using skeletal mouse mdx
cells, a model of Duchene’s muscular dystrophy where higher activity peptide-PMO conjugates were identified
compared with the starting peptide-PMO. The results demonstrate the power of the parallel synthesis methods for
increasing the speed of optimization of peptide sequences in conjugates of PMO for therapeutic screening.
Introduction
Duchenne muscular dystrophy (DMD) is a severemuscle-wasting disease in young boys caused by deletions
or point mutations in the pre-mRNA for dystrophin that result in
out-of-frame transcripts and hence a nonfunctional truncated
dystrophin protein. In recent years, synthetic splice-switching
oligonucleotides (SSO) have been developed as new treatments
for DMD whereby an SSO is targeted to the pre-mRNA and
mediates splicing redirection to restore the reading frame of the
dystrophin gene via exon skipping, and thus to generate a
shorter but functional dystrophin protein isoform [1,2]. Several
SSO chemistries have been developed for exon skipping in
DMD and other neuromuscular diseases [3,4], but of these only
two SSO chemical types have been used in clinical trials,
namely 2¢-O-methyl phosphorothioates (2¢-OMe/PS) [5] and
phosphorodiamidatemorpholino oligonucleotides (PMO) [6,7].
Peptide (P)-PMO conjugates consisting of charge neutral
PMO conjugated to cell-penetrating peptides (CPPs) have been
designed in order to enhance delivery into cells. The most
effective CPPs are Arg-rich [8,9]. P-PMOs have shown sig-
nificantly improved uptake in an mdx mouse model of DMD,
where the dystrophin gene has a pointmutation in exon 23, both
inmuscle cell culture and in skeletal muscle following systemic
delivery [10–12]. However, good heart activity has typically
required repeated and very high dose administrations [13].
Starting from a derivative of the already known CPP pe-
netratin containing six additional arginine residues (R6-Pen)
[14], we derived a series of peptide nucleic acid (PNA)/PMO
internalization peptides (Pips) with improved stability to
serum proteolysis. In collaborative studies with the labora-
tory ofWood and colleagues, two of these Pip peptides, Pip2a
and Pip2b, when conjugated to a dystrophin exon 23–specific
peptide nucleic acid (PNA) SSO, showed strong exon skip-
ping and dystrophin production in mdx muscle cells and
following intramuscular injection into the tibialis anterior
(TA) muscle of the mdx mouse [15]. Further Pip5 peptide
versions as PMO conjugates showed remarkably high dys-
trophin production in heart in addition to skeletal muscle,
following systemic delivery into mdx mice [16]. Such
Pip peptides are comprised of a hydrophobic core region
flanked on each side by an Arg-rich domain containing
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aminohexanoic (X) and b-alanine (B) spacers. In a further
Pip6 series of peptides, the hydrophobic core was found to be
essential for dystrophin production in heart [17]. Pip6a-PMO
in particular has become a paradigm for physiology and other
mouse studies in DMD and other neuromuscular diseases.
A significant problem in developing novel CPPs tuned
specifically for delivery into different cell types or tissues has
proved to be the lack of a rapid method for synthesis of se-
quence variants of CPPs conjugated to a PMO or PNA cargo
on suitable scale for cell culture testing to allow CPP candi-
dates to emerge for subsequent in vivo studies. Recently, we
developed a new method, known as SELection of PEPtide
CONjugates (SELPEPCON), for the parallel synthesis of
peptide-biocargo conjugates that utilizes affinity purification
for rapid isolation of the conjugates andwhich avoids the need
for time-consuming high-performance liquid chromatography
(HPLC) conjugate purifications [18]. This methodology was
applied initially to create a parallel-synthesized CPP library of
a PNA cargo specifying the well-known splice-redirecting
705 sequence [19]. A conjugate library of some 78 CPP-PNA
members was tested for their abilities to induce splicing re-
direction in HeLa pLuc705 cells and the results showed proof-
of-principle as to how SELPEPCON could be applied for
conjugate cell screening purposes.
We now extend this SELPEPCON methodology for use
with a PMO cargo. We describe the design and synthesis of a
small library of peptide-PMO conjugates through use of a
biotinylated azido connector peptide pre-joined to the PMO
cargo, which was then conjugated via copper-catalyzed ‘‘click’’
chemistry to alkyne-functionalized peptides in the library. After
immobilization on streptavidin cartridge columns, the conju-
gates were released by reductive cleavage of a reversible dis-
ulfide linkage, cysteine-capped, and desalted. The conjugate
library was tested for exon skipping biological activity using
mouse mdx muscle cells in culture and this showed substantial
peptide sequence dependence. A second method of SELPEP-
CON peptide-PMO conjugation using direct amide conjugation
of a C-terminally extended peptide library to the PMO was
also described and exemplified by use of an arginine-rich pep-
tide, Pip6a. The methods are applicable in principle for rapid
screening of CPP-PMO conjugates with varying peptide se-
quences for targeting mRNA or pre-mRNA in any disease
where PMO can be used for steric blocking antisense activity.
Materials and Methods
9–fluorenylmethoxycarbonyl (Fmoc) protected l-amino
acids, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium
(PyBOP), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluro-
nium hexafluorophosphate (HBTU), and the Fmoc-b-Ala-OH
preloaded Wang resin (0.19mmol/g) were obtained from
Merck. Fmoc-L-bis-homopropargylglycine-OH was obtained
from Chiralix. HPLC grade acetonitrile, methanol, and syn-
thesis gradeN-methyl-2-pyrrolidone (NMP) were from Fisher
Scientific. Peptide synthesis grade N,N-dimethylformamide
(DMF) and diethyl ether were obtained from VWR Interna-
tional). Piperidine and trifluoroacetic acid (TFA) were ob-
tained from Alfa Aesar. H-Rink amide chemmatrix resin
was purchased from PCAS Biomatrix Inc.. TBTA [tris-
(benzyltriazolylmethyl)amine] was synthesized according to
a literature procedure [20]. PMO was purchased from
Gene Tools Inc. (Philomath, OR). Chicken embryo extract
and horse serum were obtained from Sera Laboratories
International Ltd.. Interferon was obtained from Roche
Applied Science. All other reagents were obtained from
Sigma-Aldrich unless otherwise stated. Matrix-assisted-
laser-desorption/ionization-time of flight (MALDI-TOF)
mass spectrometry was carried out using a Voyager DE Pro
BioSpectrometry workstation. A stock solution of 10mg/mL
of a-cyano-4-hydroxycinnamic acid or sinapinic acid in 60%
acetonitrile in water was used as matrix. Mass accuracy for
the instrument is – 0.1%.
Azido connector peptide (2)
The solid-supported connector peptide BWXCG (1) (B,
beta-alanine; X, aminohexanoic acid) (Fig. 1) was synthe-
sized on a 100-mmol scale using a CEM LibertyTM micro-
wave Peptide Synthesizer and Fmoc chemistry following
manufacturer’s recommendations. After the solid phase
peptide synthesis, the solid-supported peptide was removed
from the synthesizer and 5-azidopentanoic acid was manually
coupled using HBTU/1-hydroxy-7-aza-benzotriazole (HOAt)/
diisopropylethylamine (DIPEA) (2.5:2.5:5.0) at room tem-
perature for 15minutes to give solid supported azido peptide 2.
The azido peptide was released from the solid support by
treatment with a cleavage cocktail consisting of trifluoroacetic
acid (TFA), triisopropylsilane (TIPS), H2O, phenol
(91.5%:5%:2.5%:1%, 5mL) for 3 hours at room temperature.
After peptide release, excess TFA was removed by a flow of
nitrogen. The crude peptide was precipitated by the addition of
cold diethyl ether (15mL) followed by centrifugation at
2,500 rpm for 2 minutes. The crude peptide pellet was washed
thrice with cold diethyl ether (3· 15mL). The crude peptide
was dissolved in 7mL 25% dimethylsulfoxide (DMSO) in
0.1% TFA and purified by reversed phase (RP)-HPLC using a
Phenomenex Jupiter column (21.2· 250mm, C18, 10mm) at
a flow rate 10mL/minutes with the following gradient (A:
0.1%TFA;B: 90%CH3CN, 0.1%TFA) 0–2minutes 5%B, 2–
35 minutes 5%–60% B, 35–40 minutes 60%–90% B. The
fractions containing the desired azido peptide (3) were com-
bined and lyophilized to yield the peptide as a white solid (24%
yield) (mass expected 673.78; mass obtained 673.20).
Biotinylated azido connector peptide (5)
To a solution of the azido connector peptide (3) (6 mmol) in
DMSO (200mL) was added water (600mL). To this solution,
EZ-link HPDP-Biotin (4) (800 mL of 15mM in DMSO) and
sodium phosphate buffer pH 7.4 (200mL of 100mM) were
added and the resultingmixture was left to stand for 2 hours at
room temperature. The reaction was quenched by the addi-
tion of 0.1% TFA (2mL). This solution was filtered using a
solid phase extraction reservoir (12mL, Agilent Techno-
logies), fitted with a polypropylene frit (20mm, Agilent
Technologies) and the desired product was isolated using
RP-HPLC using a Phenomenex Jupiter column (21.2 ·
250mm, C18, 10 mm) at a flow rate 10mL/minute with the
following gradient (A: 0.1% TFA; B: 90% CH3CN, 0.1%
TFA): 0–30 minutes 10%–70% B, 30–33 minutes 70%–90%
B. The fractions containing desired modified peptide were
combined and lyophilized to yield the desired biotinylated
azido connector peptide 5 as a white solid (78% yield) (mass
expected 1,102.40; mass obtained 1,101.32).
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Biotinylated azido connector peptide
derivatized PMO (6)
An unmodified 25-mer PMO antisense sequence for mouse
dystrophin exon-23 (GGCCAAAACCTCGGCTTACCTG
AAAT) with an unfunctionalized C-terminus was used.
The connector peptide was conjugated to the 3¢-end of the
PMO through its C-terminal carboxyl group. To a solution of
azide and biotin functionalized peptide (2500 nmol) in N-
methylpyrrolidone (NMP, 80mL) were added HBTU (19.2mL
of 0.3M in NMP, 2.5 eq), HOAt in (16.7 mL of 0.3M NMP,
2 eq), DIPEA (6.25 mmol, 1.0 mL, 2.5 eq), and PMO (200mL
of 5mM in DMSO, 0.5 eq). The mixture was left for 2 hours
at 40C and the reaction was quenched by the addition of
0.1% TFA (1mL). This solution was purified by RP-HPLC
using a Phenomenex Jupiter column (4.6· 250mm, C18,
5 mm) with the following gradient (A: 0.1% TFA, B: 90%
CH3CN, 0.1%TFA) 0–30minutes 10%–60%B, 30–33minutes
60%–90% B. The fractions containing the desired compound
were combined and lyophilized to yield the PMO-connector
peptide derivative 6 as a white solid (28% yield) (mass ex-
pected 9,497.48; mass obtained 9,490.53).
Preparation of a library of Apolipoprotein
E peptide variants
The first amino acid, Fmoc-L-bis-homopropargylglycine-
OH, was coupled manually to the solid support (H-Rink Amide
Chemmatrix, 0.53mmol/g loading) using a 1.5 molar excess
following HBTU activation. The remainder of each sequence
was prepared on a 5-mmol scale using an Intavis Parallel Peptide
Synthesizer by applying standard Fmoc chemistry and following
manufacturer’s recommendations. Double coupling steps were
used with a PyBOP/NMM coupling mixture followed by acetic
anhydride capping after each step. The N-terminally acetylated
peptides were cleaved from the solid support by treatment with
a cleavage cocktail consisting of trifluoroacetic acid (TFA),
triisopropylsilane (TIPS), H2O, and phenol (91.5%: 5%: 2.5%:
1%, 1.5mL) for 3 hours at room temperature. The solutionswere
concentrated to a volume of 500mL using a flow of nitrogen and
diluted with water (5mL). The resulting mixture was loaded on
a 20-cc Oasis HLB (hydrophilic-lipophilic balance) cartridge
(Waters), which was previously washed with acetonitrile
(10mL) and equilibrated with 0.1% TFA (2· 10mL) and 5%
acetonitrile in 0.1% TFA (2· 10mL). The peptide was eluted
with 40% acetonitrile in 0.1% TFA (10mL). The solution ob-
tained was lyophilized and the yield was calculated using the
weight obtained, corrected for the amount of TFA salts based
on the number of positive charges present in the peptide.
Conjugate synthesis by copper-catalyzed
click chemistry
A mixture was prepared containing connector peptide-
functionalized PMO (30 nmol of a 1mM solution in water),
alkyne functionalized peptide (150 nmol of a 10mM solution
inNMP), and 2,6-lutidine (15,000 nmol). A premixed solution
FIG. 1. The synthesis of the biotinylated azido connector peptide and subsequent C-terminal amide attachment to a phos-
phorodiamidate morpholino oligonucleotide (PMO) cargo. DIPEA, diisopropylethylamine; HBTU, 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate; HOAt, 1-hydroxy-7-aza-benzotriazole; HPLC, high-performance liquid
chromatography; N(Boc), N(t-butyloxycarbonyl); S(Trt), S(Trityl); TFA, trifluoroacetic acid.
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containing CuSO4-TBTA solution (12mL of 20mM, 240 nmol)
in a 1:1mixture ofH2O/DMSO and sodium ascorbate (30mL of
a 20mM solution in water, 600 nmol) was added to this mix-
ture. The mixture was left for 2 hours and quenched by the
addition of ethylenediaminetetraacetic acid (EDTA) (900mL of
10mM in TBS 10% CH3CN).
The resulting solution was loaded in two batches of 500mL
on a streptavidin HP SpinTrap (GE Healthcare) column and
incubated for 1 hour. The column was washed with EDTA
(400mL of 10mM in TBS) and with TBS (5· 400mL). The
conjugate was released from the resin by 2· 20 minutes reac-
tion with tris(2-carboxyethyl)phosphine (TCEP) (2· 400mL of
10mM in 20% CH3CN TBS) and the resin washed with TBS
(200mL). The resulting solutions were combined and lyophi-
lized. The resultant white solid was dissolved in 0.1% TFA,
10%CH3CN (500mL) and loaded on an equilibrated 1-cc Oasis
HLB cartridge (Waters) together with 0.1%TFA (500mL). The
column was washed with 0.1% TFA (3· 1mL), 5% CH3CN
in 0.1% TFA (3· 1mL), and 10% CH3CN in 0.1% TFA
(1· 1mL). The conjugate was released from cartridge via the
addition of 60% CH3CN in 0.1% TFA (500mL). The resulting
solution was lyophilized to yield the desired conjugate as a
white solid (35%–64% yield).
Iodoacetamide capping procedure
Each conjugate (10 nmol) was dissolved in sodium bicar-
bonate solution (25mL of 0.1M, pH 8.0) and iodoacetamide
(23mg, 250 nmol) was added. The solution was left for 2
hours in darkness and diluted with water (975 mL). Excess
iodoacetamide was removed through the use of an Amicon
Ultra-1mL centrifugal filter unit with a 3,000 molecular
weight cutoff. The resulting filtrate was lyophilized to yield
the desired thiol-capped product (55%).
Alternative capping method of free thiol
groups of conjugates (unsuitable
for very hydrophobic peptides)
Following the click reaction and subsequent release from
the strepavidin HP spin trap columns using TCEP, the un-
purified solution was treated with a large excess of iodo-
acetamide (25 eq, 139mg, 1,500 nmol). The solution was left
for 2 hours in the dark and diluted with water (4mL). Excess
iodoacetamide and TCEP were removed through the use of
Amicon Ultra-5 centrifugal filter units with a 3,000 mo-
lecular weight cutoff. The resulting filtrate was lyophilized to
yield the desired S-capped product (65%).
Alternative method of conjugate synthesis
without precoupling with a connector
peptide: Pip6a-SH-PMO
Pip6a-SH (Ac-RXRRBRRXRYQFLIRXRBRXRCXB,
where B is b-alanine and X is aminohexanoic acid) was
synthesized as a C-terminal carboxylic acid on an Fmoc-b-
Ala-Wang resin (100–200mesh, 0.6mmol/g) using Fmoc
chemistry on a CEM LibertyTM microwave peptide syn-
thesizer. The side chain protecting groups used were tri-
fluoroacetic acid labile. The peptide was synthesized on a
0.1mmol scale using a 5-fold excess of Fmoc-protected
amino acids (0.5mmol), which were activated using PyBOP
(5-fold excess) in the presence of DIPEA. Piperidine (20%
v/v in DMF) was used to remove the Fmoc protecting
groups. The coupling was carried out once at 75C for 5
minutes at 60-watt microwave power except for arginine
residues, which were coupled twice each. Each deprotection
reaction was carried out at 75C twice, once for 30 seconds
and then for 3 minutes at 35-watt microwave power.
Once synthesis was complete, the support was washed with
DMF (3· 50mL) and the N-terminus of the solid phase bound
peptide was acetylated with acetic anhydride in the presence of
DIPEA. The peptide was cleaved from the solid support by
treatment with a cleavage cocktail consisting of trifluoroacetic
acid (TFA), 3,6-dioxa-1,8-octanedithiol, H2O, triisopropylsi-
lane (TIPS) (94%:2.5%:2.5%:1%, 10mL) for 3 hours at room
temperature. Excess TFA was removed by a flow of nitrogen.
The cleaved peptide was precipitated via the addition of ice-
cold diethyl ether and centrifuged at 3,000 rpm for 2 minutes.
The peptide pellet was washed in ice-cold diethyl ether thrice.
The crude peptide was dissolved in water, analyzed and puri-
fied by RP-HPLC on Phenomenex Jupiter columns (analytical:
4.6· 250mm, C18, 5mm) and (preparative: 21.2· 250mm,
C18, 10mm) respectively. A flow rate of 1.5mL/minute for
the analytical column and 10mL/minute for the preparative
column with the following gradient (A: 0.1% TFA, B: 90%
CH3CN, 0.1% TFA) 0–2 minutes 5% B, 2–35 minutes 5%–
60% B, 35–40 minutes 60%–90% B was used. The fractions
containing the desired peptide were combined and lyophilized
to give the product as a white solid (55% yield) (mass expected
3,169; mass obtained 3166).
Biotinylation of Pip6a-SH
To a solution of of Pip6a-SH (2mmol) inDMSO (66mL) was
added water (200mL). To this solution EZ-link HPDP-Biotin
(267mL of 15mM in DMSO) and sodium phosphate buffer pH
7.4 (66mL of a 100mM solution) were added and the resulting
mixture was left to stand for 2 hours at room temperature. The
reaction was quenched by the addition of 0.1% TFA (0.66mL).
This solution was filtered using a solid-phase extraction res-
ervoir (12mL, Agilent Technologies), fitted with a polypro-
pylene frit (20mm, Agilent Technologies) and the desired
product was isolated using RP-HPLC, a Phenomenex Jupiter
column (21.2· 250mm, C18, 10mm) was used at a flow rate
10mL/minute with the following gradient (A: 0.1% TFA, B:
90% CH3CN, 0.1% TFA) 0–30 minutes 10%–70% B, 30–33
minutes 70%–90% B. The fractions containing the desired
peptide were combined and freeze-dried to yield biotin-
modified Pip6a-SH as awhite solid (48%yield).Mass expected
3597.32, mass obtained 3594.32.
Conjugation of biotinylated Pip6a-SH
to PMO and subsequent capping
An unmodified 25-mer PMO antisense sequence targeting
mouse dystrophin exon-23 (GGCCAAAACCTCGGCT-
TACCTGAAAT) with an unfunctionalized C-terminus was
purchased from Gene Tools Inc.. The biotinylated Pip6a-SH
was conjugated to the 3¢-end of the PMO through its
C-terminal carboxyl group. To a solution of biotin-functio-
nalized peptide (625 nmol) in N-methylpyrrolidone (NMP,
20 mL) were added HBTU (4.8 mL of 0.3M in NMP, 2.5 eq),
HOAt (4.2 mL of 0.3M NMP, 2 eq), DIPEA (0.25 mL,
1.56 mmol, 2.5 eq), and PMO (50mL of 5mM in DMSO, 0.5
eq). The reaction was carried out at 40C for 2 hours and
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quenchedwith TBS in 10%CH3CN. The resulting solutionwas
loaded in two batches of 500mL on a streptavidin HP SpinTrap
column (GE Healthcare) and incubated for 1 hour. The column
was washed with EDTA (400mL of 10mM in TBS) and with
TBS (5· 400mL). The conjugate was released from the resin
by 2· 20-minute reaction with TCEP (2· 400mL of 10mM in
20%CH3CN in TBS) and the resin washed with TBS (200mL).
The resulting solutions were combined and lyophilized.
The resultant white solid was dissolved in 0.1% TFA, 10%
CH3CN (500 mL) and loaded on to an equilibrated 1-cc Oasis
HLB cartridge (Waters) together with 0.1% TFA (500mL).
The column was washed with 0.1% TFA (3· 1mL), 5%
CH3CN in 0.1% TFA (3 · 1mL) and 10% CH3CN in 0.1%
TFA (1 · 1mL). The conjugate was released from the column
via the addition of 60% CH3CN in 0.1% TFA (500mL). The
resulting solution was lyophilized to yield the desired con-
jugate as a white solid (42% yield).
Conjugates (10 nmol) were dissolved in sodium bicar-
bonate solution (25 mL of 0.1M, pH 8.0), and iodoacetamide
(23mg, 250 nmol) was added. The solution was left for 2
hours in the dark and diluted with water (975 mL). Excess
iodoacetamide was removed through the use of Amicon
Ultra 1-mL centrifugal filter unit with a 3,000 molecular
weight cut off. The resulting filtrate was lyophilized to yield
the desired S-capped product (55%) [mass expected 11,622;
mass obtained 11,645 (mass +Na)].
Cell culture
Murine H2k mdx myoblasts were cultured in gelatin
(0.01%)-coated flasks at 33C, under 10%CO2 in Dulbecco’s
modified Eagles medium (DMEM;, PAA laboratories) sup-
plemented with 20% heat-inactivated fetal bovine serum
(FBS Gold, PAA Laboratories), 2% chicken embryo extract
(Seralab), 1% penicillin-streptomycin-neomycin antibiotic
mixture (PSN, Gibco), and 3 pg/mL g-interferon (Roche).
Cells were seeded in gelatin (0.01%)-coated 48-well plates
at a density of 2· 105 cell/mL and left for 2 days at 33C,
10% CO2. To differentiate into myotubes, cells were further
grown in DMEM supplemented with 5% horse serum (Sig-
ma) and 1% PSN at 37C under 5% CO2 for 2 days.
Cell transfection
Cells were incubated with ALB conjugates (see Table 1),
Pip6a-PMO prepared using the SELPEPCON method, and
Pip6a-PMO and apolipoprotein E (ApoE)-PMO prepared by
direct conjugation, which were made in serum-free Opti-
MEM, and 200 mL was added to each well as duplicates and
incubated at 37C for 4 hours. The transfection medium was
then replaced with DMEM supplemented with 5% horse se-
rum and 1% PSN and the cells incubated for a further 20
hours at 37C. Cells were washed with PBS and 0.5mL of
TRI RNA (Sigma) isolation reagent was added to each well.
Cells were frozen at - 80C for 1 hour.
RNA extraction and nested reverse transcription-
polymerase chain reaction analysis
Total cellular RNA was extracted using TRI reagent with an
extra further precipitation with ethanol. The purified RNA was
quantified usingNanodropND-1000 (ThermoScientific). The
RNA (400ng) was used as a template for reverse transcription-
polymerase chain reaction (RT-PCR) using a OneStep RT-PCR
Kit (Roche). The primer sequences used were Exon20F0 5¢-
CAGAATTCTGCCAATTGCTGAG-3¢ and Exon26Ro 5¢-
TTCTTCAGCTTGTGTCATCC-3¢. The cycle conditions for
the initial reverse transcription were 50C for 30 minutes and
94C for 7 mintes for one cycle followed by 30 cycles of 94C
for 20 secconds, 55C for 40 seconds, and 68C for 80 seconds.
One microlitre of the RT-PCR product was used as template for
the second PCR step. The primer sequences were Exon20Fi 5¢-
CCCAGTCTACCACCCTATCAGAGC-3¢ and Exon2Ri 5¢-
CCTGCCTTTAAGGCTTCCTT-3¢. The amplification was
carried out using 0.5U of SuperTAQ in 25 cycles at 94C
for 30 seconds, 55C for 1 minute and 72C for 1 minutes.
the products were separated by electrophoresis using 1.5%
agarose gel.
Data analysis
The images of agarose gels were taken on a Molecular
Imager ChemiDocTM XRS + imaging system (BioRad) and
the images were analyzed using Image Lab (V4.1). Microsoft
Table 1. Yields of Parallel Synthesis of the ALB-Peptide Library and ALB-PMOEx23
Conjugate Synthesized by the Synthesis Approach Shown in Fig. 2
Peptide Sequence (N- to C-term) Yield peptide Yield conjugate
ALB1 L R K L R K R L L R Bpg 42% 25%
ALB2 R L L R K R L K R L Bpg 36% 29%
ALB3 L K L R R K R L L R Bpg 32% 20%
ALB4 R R R R K K L L L L Bpg 37% 17%
ALB5 L L L L K K R R R R Bpg 54% 30%
ALB6 K L L R R R R L L K Bpg 45% 22%
ALB7 R R K L L L L K R R Bpg 30% 20%
ALB8 L L K R R R R K L L Bpg 38% 21%
ALB9 A R K A R K R A A R Bpg 55% 45%
ALB10 I R K I R K R I I R Bpg 47% 37%
ALB11 F R K F R K R F F R Bpg 35% 55%
ALB12 W R K W R K R W W R Bpg 52% 29%
ALB13 N R K N R K R N N R Bpg 63% 43%
ALB14 H R K H R K R H H R Bpg 39% 28%
ALB15 L R R L R R R L L R Bpg 41% 56%
ALB16 L K K L K K K L L K Bpg 44% 43%
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Excel was used to analyze and plot the exon-skipping assay
data, which were expressed as the percentage of exon-23
skipping from at least three independent experiments.
Results
Adaptation of SELPEPCON for P-PMO
conjugate synthesis
We first applied the principles of SELPEPCON [18] to
design chemistry for parallel P-PMO conjugate synthesis.
Similar to the synthesis of P-PNA, we chose once again
copper-catalysed alkyne-azide ‘‘click’’ chemistry for stable
conjugation of a peptide library to a PMO cargo (Fig. 2). In
adaptation of SELPEPCON to P-PMO synthesis, we had at
first utilized a commercially available PMO cargo functio-
nalized at the 3¢-terminus with a thiol linker, to which a biotin
was subsequently attached, and at the 5¢-end with a primary
amino group, to which an azido group was subsequently in-
troduced ready for conjugation to the peptide library.
Although this route of SELPEPCONwas successful (data not
shown), it was more convenient and less expensive to develop
methodology that utilized unmodified and unfunctionalized
PMO. Therefore, to facilitate the desired cargo functionaliza-
tion, unmodified PMO was precoupled on its 3¢-end to a short
connector peptide containing an azido group and a cysteine
residue (Fig. 1). This allowed both attachment of a biotin tag
through a reversible disulfide linker and click conjugation with
an alkyne-containing peptide library. The method then involves
rapid purification of the conjugated product via immobilization
on a streptavidin cartridge column, washing, release from the
support, and desalting. We also report an optional iodoaceta-
mide capping step in order to mask any potential negative in-
fluence of the released cysteine thiol group on conjugate activity.
To achieve such syntheses, the PMO component was first
coupled to the short connector peptide (Fig. 1). The connector
peptide, the sequence of which was chosen to ensure significant
serum stability [BWXCG, 1], was synthesized on solid phase
using a Liberty microwave peptide synthesizer. Once the syn-
thesis was complete, 5-azidopentanoic acid was coupled man-
ually to the N-terminus of 1 to yield the supported azido
connector peptide 2. The supported azido connector peptide 2
was deprotected and cleaved from the solid support to give the
azido peptide 3. A biotin group was introduced on to 3 by dis-
ulfide bridge formation via reaction of the cysteine residue
with commercially available N-[6-(biotinamido)-hexyl]-3-(2-
pyridyldithiopropionamide (EZ-link HPDP biotin, 4). This re-
action provided the N3-BWXCG-S-S-biotinylated peptide 5
in good yield after HPLC purification. The biotinylated azido
connector peptide-PMO conjugate 6 was prepared by reaction
of the 3¢-end of the PMO with the C-terminal carboxylic acid
moiety of the peptide to form an amide bond. The PMO used
was a 25-mer previously used for exon 23 skipping of the dys-
trophin gene in mouse mdx muscle [16,17].
Peptide and P-PMO library synthesis
For a trial peptide library, we chose a short cationic 10-
residue peptide (LRKLRKRLLR, ALB1 in Table 1) ApoE
(residues 141–150) as an example. This peptide has been
known for some years as a peptide that binds to the LDL
receptor [21]. More recently ApoE peptide has been shown,
when displayed on nanoliposomes, to have the potential to
direct such liposomes and their contents across the blood–
brain barrier (BBB) [22]. ApoE peptide and its variants could
be of interest as PMO conjugates in respect of whether PMO
can be transported across the BBB in addition to enhancing
entry into muscle cells.
Peptide variants synthesized in the 16-member library
chosen included hydrophobic amino acid substitutions [e.g.,
leucine (L) to isoleucine (I); L to phenylalanine (F); and L
to alanine (A)] as well as rearrangement of the positions of
FIG. 2. SELPEPCON peptide (P)-PMO conjugate synthesis by conjugation of a biotinylated azido connector peptide
functionalized PMO with a peptide library via alkyne-azide click chemistry followed by purification by streptavidin
immobilization and release, and optional cysteine capping using iodoacetamide. TCEP, tris(2-carboxyethyl)phosphine;
SELPEPCON, SELection of PEPtide CONjugates.
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the cationic residues lysine (K) and arginine (R) (Table 1).
For each peptide, a C-terminal alkyne was introduced using
Fmoc-L-bis-homopropargylglycine (Fmoc-Bpg) through an
initial manual coupling to the H-rink amide solid support
prior to peptide assembly. The peptide library was syn-
thesized using an Intavis Parallel Peptide Synthesizer by
standard Fmoc chemistry [18]. After the final Fmoc de-
protection step, the support was N-terminally acetylated
and the peptides cleaved from the support by standard TFA
treatment. The peptides were rapidly isolated by solid
phase extraction (SPE) using Oasis HLB cartridges in good
yields (Table 1). MALDI-TOF mass spectrometric analysis
revealed in all cases that the major product was the ex-
pected peptide with only minor amounts of side products
present (see Supplementary Table S1 and Supplementary
Figs. S1–S9; Supplementary Data are available online at
www.liebertpub.com/nat). Cleavage, deprotection, and
purification of all 16 peptides were carried out in just one
day, thus demonstrating quick and easy parallel synthesis
and purification.
Peptide-PMO conjugates were synthesized, purified, and
isolated in parallel (Fig. 2). Thus alkyne peptides were con-
jugated to the biotinylated azido connector peptide-PMO
conjugate 6 through copper-mediated alkyne-azide cou-
pling reactions. To stabilize the active copper (I) species, 2,6-
lutidine and tris(benzyltriazolylethyl) amine (TBTA) were
used [18]. After 2 hours, reactions were quenched by addition
of EDTA and the conjugates (7) immobilized on a strepta-
vidin-functionalized Sepharose support held in SpinTrap
centrifuge tubes (conjugates 8). Following several washes to
remove the excess peptide and reaction reagents, the conju-
gates (9) were released from the support by addition of a
solution containing 10mM (TCEP). Centrifugation led to
isolation of the products in the solution, while the biotin tag
remained attached to the support. Conjugates were lyophilized
and any remaining buffer, and TCEP was removed by solid
phase extraction (SPE) using Oasis HLB cartridges in rea-
sonable yields. Representative mass spectra for P-PMO prod-
ucts are shown in Supplementary Figs. S10–S16 and HPLC
traces for a representative peptide (ALB1) and its P-PMO
conjugate are shown in Supplementary Figs. S17 and S18.
Assay of the ApoE-PMO library in mdx
muscle cells and capping
Preliminary analysis of conjugates in an exon-skipping
assay in mouse mdx muscle cells suggested that significant
exon skipping activity was lost for ALB1 compared to a
directly conjugated ApoE-PMO conjugate (data not shown).
Accordingly, we decided to investigate whether capping of
the free thiol functionality of the cysteine in the connector
peptide could restore exon-skipping activity. Although the
thiol could be successfully capped after the desalting step of
the synthesis via reaction with a large excess of iodoaceta-
mide (conjugates 10, Fig. 2), this required a subsequent extra
lyophilization resulting in a slight decrease in overall yield.
Therefore, following cleavage from the solid support with
TCEP, the resultant solution was treated in situ with a large
excess of iodoacetamide. MALDI-TOF analysis showed that
capping of the free thiol occurred successfully and thus ex-
cess TCEP and iodoacetamide were then removed using the
centrifugal filtration units.
The ALB-PMO conjugate library was screened at 1 and
2 mM concentrations for their abilities to induce exon 23
skipping in the well-established skeletal muscle model of
DMD (i.e., murine H2kmdx cells). In vitro differentiated H2k
mdx myotubes were treated with ALB-PMO conjugates and
exon skipping was evaluated after 24-hour treatment by
nested RT-PCR. All conjugates induced exon 23–skipping in
a dose dependent manner (Fig. 3). ApoE-PMO prepared
using the conventional method of direct conjugation of the
C-terminal acid of the peptide to the 3¢-amine of the PMO via
the formation of an amide linkage was used as a positive
control in these experiments. Note that the level of exon
skipping for ALB1-PMO is only slightly lower than for a
control ApoE-PMO where the ApoE peptide is directly
conjugated to the PMO. This shows that the additional
BWXC(S-cap)G spacer in ALB1-PMO does not reduce the
exon skipping activity significantly.
ALB1 to ALB8 all contained the same number of arginine
(four), lysine (two), and leucine (four) residues, but placed in
different relative positions. It can be seen (Fig. 3) that ALB4,
6, and 8, where all four arginine residues were clustered, gave
higher levels of exon skipping than for conjugates where the
arginines were not clustered (ALB1, 2, 3, 5, and 7). Inter-
estingly, when all the leucine residues were replaced by al-
anines and when arginine residues were not clustered
(ALB9), this conjugate also showed a higher level of exon
skipping than the original ApoE peptide (ALB1). However,
replacement of the leucine residues either by isoleucine,
phenylalanine, tryptophan, or by asparagine (ALB10–13)
resulted in a drop in exon skipping activity. Additionally,
replacement of leucine residues by histidines (ALB14) led to
higher exon skipping activity compared to the starting ApoE
peptide (ALB1). Replacement of all lysine residues by argi-
nines (ALB15) led to an increase in exon skipping. However,
replacement of all arginine residues by lysines (ALB16) led
to a sharp decrease in the level of exon skipping. This peptide
acts essentially as a ‘‘baseline’’ for exon skipping activity and
also shows that exon skipping is not completely lost in the
absence of Arg residues.
These results show the power of the SELPEPCON method
in the ability to produce variant peptides with higher levels of
biological activity in a cell assay.
FIG. 3. Analysis of the ALB-PMO conjugate library
(Table 1) showing levels of exon 23 skipping in H2k mdx
muscle cells for the different conjugates. Differentiated H2k
mdx cells were incubated for 4 hours with conjugates at the
indicated concentrations.
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An alternative method for parallel P-PMO synthesis
Although the above P-PMO synthesis procedures are
suitable in principle for most peptides (other than those
containing cysteine, which could perhaps undergo disulfide
shuffling during the syntheses), we wished to simplify the
conjugation chemistry, especially for arginine-rich peptides,
such as Pip6a, which are used most frequently in our labo-
ratory. Rather than initial pre-coupling of a PMO with an
azido connector peptide ready for click conjugation, it is
possible to dispense with the connector peptide and instead
carry out direct amide conjugation of C-terminally extended
peptide libraries containing a biotin for rapid purification to
the PMO.
To exemplify the principle, a single peptide Pip6a was
synthesized on solid phase with a C-terminal extension of an
additional cysteine residue and an XB spacer (Fig. 4) (note
that for SELPEPCON, a series of such peptides would be
prepared in parallel). Once synthesis was complete the pep-
tide was N-acetylated and cleaved from the support. The
peptide was biotinylated in a similar fashion to that used
previously using EZ-link HPDP Biotin. Conjugation of the
peptide to PMO was carried out in solution via C-terminal
activation of the peptide in the presence of HBTU and HOAt.
After 2 hours the reaction was quenched with TBS in CH3CN
and the P-PMO conjugate immobilized as before on a
streptavidin-functionalized Sepharose support held in a
SpinTrap centrifuge tube. Following several washes, the
desired conjugate was released from the solid support using
TCEP, and the resultant free thiol was capped by reaction
with iodoacetamide and impurities removed by solid-phase
extraction using Oasis HLB cartridges (rather than the fil-
tration that was used in the first method) to give the Pip6a-
conjugated PMO in good yield. Note that in this method, the
excess of biotinylated peptide is also immobilized on the
solid support and is released together with conjugate, but
such excess peptide is then removed during the final solid-
phase extraction.
Comparison of exon skipping levels in mouse mdx muscle
cells showed that the presence of the extra capped thiol group
and XB spacer in the P-PMO prepared using this alternative
SELPEPCON method (Pip6a-SCap-PMO) had no signifi-
cant effect on the exon skipping activity (Supplementary
Fig. S19).
Discussion
We have demonstrated convenient and rapid chemical
procedures suitable for parallel synthesis of a library of
peptide conjugates of PMO via the SELPEPCON approach.
In the first method, click conjugation occurs in solution
between members of an alkyne-functionalized peptide li-
brary with a PMO that is pre-coupled with a biotinylated
azido connector peptide. Streptavidin immobilization, re-
ductive release, and capping of the released cysteine residue
forms a series of P-PMO conjugates that are pure enough to
be used directly in a biological cell assay, in this case using
mouse mdx cells and screening for exon skipping using an
RT-PCR method. It is important to note here that the in-
sertion of a BWXC(S-cap)G spacer between peptides and
FIG. 4. Alternative route to SELPEPCON P-PMO synthesis, involving synthesis of peptides C-terminally extended with
C-X-B and subsequently C-terminal amide conjugated to a PMO cargo. X, aminohexanoic acid; B, beta-alanine.
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PMO cargo did not result in significant loss of exon skipping
activity (Fig. 3), nor was any difference seen in exon skipping
using a C(S-cap)XB spacer in the second method com-
pared with directly conjugated Pip6a-PMO (Supplementary
Fig. S19). In a similar way, conjugation of Pip peptides to
either N- or C-termini of PMO is known to lead to similar
levels of exon skipping [23]. All these data reinforce the view
that cell-penetrating peptides function predominantly as pas-
sive carriers of PMO into the nucleus of cells and therefore do
not require specific conjugation methods. However, we do not
have an explanation for why a free thiol group in the con-
nector peptide was detrimental to exon skipping in the case of
P-PMO (data not shown) but not for splicing redirection of
peptide-PNA conjugates in HeLa 705 cells [18].
Whereas the speed and convenience of the synthesis pro-
cedures is herein demonstrated, methods of assay in cell culture
vary substantially in convenience.We have used exon skipping
and RT-PCR analysis for screening P-PMO conjugates which
involves use of agarose gels and gel imaging. Suchmethods are
not as rapid, for example, as in the previously reported P-PNA
study in HeLa 705 cells, which utilized a luciferase lumines-
cence assay [18]. Hence, we synthesized in this case only a
small 16-member P-PMO library. In principle, faster screening
assays in primary muscle cells could be developed utilizing
mouse cells expressing enhanced green fluorescent protein by
splicing redirection using an oligonucleotide [24], which could
facilitate muscle cell screening of hundreds of P-PMOs syn-
thesized by the parallel SELPEPCON method.
The ApoE peptide was chosen as a model for this study
because it has potential in principle both for development as a
drug carrier across the BBB, but also as a cationic peptide that
also contains some hydrophobic residues (like Pip peptides
[17]), which might be suitable for entry into muscle cells.
Thus we found that ALB1-PMO (ApoE peptide conjugated
by the SELPEPCONmethod) does show some exon skipping
activity inmdx cells. It is not surprising that this is a lot lower
than for Pip peptides, partly because there are only four ar-
ginine residues in ApoE peptide, whereas Pip peptides, in
common with other similarly used arginine-rich peptides,
commonly contain 7–10 arginine residues [16,17].
One of the determining features of cell delivery of PMO
and PNA by CPPs both in muscle and in HeLa cells is the
number of arginine residues [9,18], as also demonstrated in
this work when arginine residues were replaced by lysine
residues, which led to a significant loss in exon 23 skipping
activity (Fig. 3, ALB16-PMO). Furthermore, as seen in Fig.
3, clustering of arginine residues (ALB4–8) increased ac-
tivity. Replacement of leucine residues by alanine, a smaller
hydrophobic amino acid (ALB9), but not by others, also led
to higher exon skipping activity in PMO conjugates than the
parent ALB1. This is reminiscent of previously published
work on the use of nonnatural hydrophobic spacers between
arginine residues [25]. Interestingly replacement of leucines
by histidines maintained the same exon skipping level as
ALB1, whichmight be as a result of a ‘‘proton sponge effect’’
[26]. Such variant ApoE derivatives synthesized could form
starting points for further peptide design and testing in a cell
or in animal models.
The second P-PMO conjugation approach does not involve
use of click chemistry but instead utilizes amide conjugation
of members of a peptide library containing a short tripeptide
3¢-extension sequence. A single example was shown in-
volving conjugation of the CPP Pip 6a to PMO. This method
is particularly suitable for peptides such as Pip6a that contain
no lysine residues, which we anticipate investigating more
extensively in forthcoming P-PMO studies of neuromuscular
diseases, such as DMD and spinal muscular atrophy. How-
ever, it should be noted that lysine-containing peptides can be
accommodated by use of orthologous 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)-3-methylbutyl protection, as we
described recently for synthesis of fluorescently labeled
P-PMO [27]. This secondmethod also involves fewer steps in
synthesis, since there is no requirement for separate con-
nector peptide synthesis, but this must be balanced against
the need for an extra deprotection step after conjugation
should lysine residues be used in the peptides, and also the
fact that excess peptides are only removed during final sold-
phase extraction, rather than during the washings following
immobilization.
In summary, we expect the methods of parallel peptide-
PMO conjugate synthesis described to substantially improve
the rate of search of peptide chemical space for desired ac-
tivity parameters in cell culture studies and hence to give rise
to an increasing number of candidates for therapeutic studies
of P-PMO.
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